NeuroScientific Biopharmaceuticals (NSB) Stock Price, News & Analysis

Company Overview

NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. It was incorporated in 2002 and is based in Cottesloe, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $5.64 million
• P/E Ratio: 17.39
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Banking
• Current Symbol: ASX:NSB
• CIK: N/A
• Web: www.neuroscientific.com
• Phone: 61 8 6382 1800
• Fax: N/A
• Employees: 283
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 17.39
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-1,070,000.00
• Net Margins: 14.66%
• Pretax Margin: N/A
• Return on Equity: 7.08%
• Return on Assets: 1.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 58.87
• Quick Ratio: 3.31

Sales & Book Value

• Annual Sales: $2.21 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.04 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 144,600,000
• Free Float: N/A
• Market Cap: $5.64 million
• Optionable: Not Optionable
• Beta: 0.57